DermTech, Inc.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in San Diego, CA.

SAN DIEGO--(BUSINESS WIRE)--DermTech, Inc. (OTC: DMTKQ) (DermTech or the Company) a leader in precision dermatology offering non-invasive skin genomics solutions, today announced that it has closed its Asset Purchase Agreement (APA) with DERM-JES Holdings, LLC. As a result of the APA, DERM-JES Holdings, LLC has acquired substantially all assets of the Company. The new entity will operate as DermTech, LLC going forward. Led by a dedicated team of dermatologists, dermatopathologists and experienc.

DermTech Completes Transaction for Asset Sale; Operations Continue Under New Ownership and Management

News for DermTech, Inc. Stock (DMTKQ)